Xenon Pharmaceuticals (XENE) Tops Q2 EPS by $2.06

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Xenon Pharmaceuticals (XENE) Tops Q2 EPS by $2.06

Xenon Reports Second Quarter 2025 Financial Results & Business Update

August 11, 2025 4:01 PM EDT

Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026
Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated
Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain
Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch
Conference call at 4:30 pm ET today

VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug... More